IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.639
NA - Nord America 1.857
EU - Europa 1.720
SA - Sud America 685
AF - Africa 55
OC - Oceania 5
Totale 6.961
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.744
SG - Singapore 1.076
CN - Cina 849
BR - Brasile 575
RO - Romania 340
HK - Hong Kong 333
SE - Svezia 270
IT - Italia 263
RU - Federazione Russa 242
DE - Germania 210
VN - Vietnam 161
FI - Finlandia 94
GB - Regno Unito 80
AR - Argentina 63
CA - Canada 54
IN - India 52
MX - Messico 47
PL - Polonia 45
ID - Indonesia 42
AT - Austria 41
BD - Bangladesh 30
FR - Francia 30
ZA - Sudafrica 28
NL - Olanda 25
JP - Giappone 24
ES - Italia 23
LT - Lituania 22
EC - Ecuador 14
TR - Turchia 14
MA - Marocco 13
IQ - Iraq 12
UA - Ucraina 11
IE - Irlanda 10
CO - Colombia 8
BE - Belgio 7
UY - Uruguay 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
EG - Egitto 6
KZ - Kazakistan 6
PY - Paraguay 6
AU - Australia 5
CL - Cile 5
PK - Pakistan 5
DO - Repubblica Dominicana 4
PH - Filippine 4
VE - Venezuela 4
IL - Israele 3
SA - Arabia Saudita 3
AZ - Azerbaigian 2
CH - Svizzera 2
GT - Guatemala 2
HN - Honduras 2
IR - Iran 2
KE - Kenya 2
NG - Nigeria 2
NP - Nepal 2
PE - Perù 2
RS - Serbia 2
TN - Tunisia 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
GE - Georgia 1
GY - Guiana 1
JO - Giordania 1
KW - Kuwait 1
LB - Libano 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
SN - Senegal 1
Totale 6.961
Salva come PNG Salva come JPEG
Città #
Singapore 546
Dallas 346
Hong Kong 331
Ashburn 201
Shanghai 187
Beijing 155
Hefei 151
New York 136
Munich 96
Los Angeles 83
Lawrence 79
Princeton 79
Milan 75
Moscow 66
São Paulo 64
Ho Chi Minh City 51
Helsinki 46
Boardman 42
Nuremberg 41
Denver 37
Warsaw 36
Cesano Boscone 33
Turku 31
Hanoi 26
Montreal 26
Santa Clara 26
Stockholm 25
Brooklyn 24
Tokyo 24
Falkenstein 23
London 23
Gatchina 22
Guangzhou 22
St Petersburg 22
Seattle 21
Vienna 20
Chennai 19
Johannesburg 19
Poplar 19
Rio de Janeiro 18
Amsterdam 16
Atlanta 16
Mexico City 15
Orem 15
Phoenix 15
Frankfurt am Main 14
Lappeenranta 14
Brasília 13
Manchester 13
Belo Horizonte 12
Chicago 12
Houston 12
Perm 12
Shenzhen 12
Tianjin 12
Boston 11
Jakarta 11
Nanjing 11
Ankara 10
Council Bluffs 10
Dublin 10
Haiphong 10
Pune 10
Toronto 10
Yekaterinburg 10
Da Nang 9
Querétaro 9
Mumbai 8
Porto Alegre 8
Romagnano Sesia 8
Biên Hòa 7
Brussels 7
Columbus 7
Goiânia 7
Guayaquil 7
Hải Dương 7
New Delhi 7
Nizhniy Novgorod 7
Tashkent 7
Turin 7
Baghdad 6
Busto Arsizio 6
Charlotte 6
Curitiba 6
Fortaleza 6
Paris 6
Pouso Alegre 6
Quito 6
Salvador 6
San Francisco 6
Sorocaba 6
St Louis 6
São Bernardo do Campo 6
The Dalles 6
Voronezh 6
Almaty 5
Boca 5
Borås 5
Buenos Aires 5
Cape Town 5
Totale 3.824
Salva come PNG Salva come JPEG
Nome #
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 224
Monkeypox in a patient with undifferentiated connective tissue disease 215
Viral bloodstream detection in mpox patients: An observational multicentric study 194
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 131
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 106
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 96
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 88
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 78
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 75
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 74
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 74
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 73
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 72
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 72
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 69
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 69
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 69
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 65
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 65
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 64
Monkeypox infection in a hemopoietic stem cell and heart transplant recipient 64
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 64
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 62
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 62
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 61
HIV viral load monitoring during monkeypox virus infection among people with HIV 61
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 61
Beyond stigma: Monkeypox infection in a 27-year-old woman 60
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 59
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-up 58
Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis 58
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 57
Isolated monkeypox proctitis among men who have sex with men 57
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 57
Monkeypox and pan-resistant Campylobacter spp infection in Entamoeba histolytica and Chlamydia trachomatis re-infection in a man who have sex with men 57
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 57
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 56
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 56
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 55
Persistent ocular mpox infection in an immunocompetent individual 54
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 53
HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy 53
Anti-Tat immunity defines CD4 + T-cell dynamics in people living with HIV on long-term cART 53
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 52
Role of multi-site sampling in the diagnosis of human Monkeypox 51
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 51
Viral hepatitis and human papillomavirus vaccination during pre-exposure prophylaxis: factors associated with missed vaccination 51
Tick-borne encephalitis seroprevalence in northern Italy: a cross-sectional study on a randomly selected population 51
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 51
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 50
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 50
Real-life use of cidofovir for the treatment of severe monkeypox cases 50
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 50
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 50
Proctitis and prostatitis by Neisseria meningitidis among MSM: A case series 49
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 49
B-cell subset alterations and correlated factors in HIV-1 infection 49
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 49
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 49
Antibiotic resistance among sexually transmitted infections: perspectives from clinical practice 48
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 48
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 47
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 46
Two individuals with potential monkeypox virus reinfection 46
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 45
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine 45
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 45
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 44
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 44
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 44
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 44
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 43
Ageing with HIV: a multidisciplinary review 43
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy 43
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 43
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 43
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 41
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 40
Mpox in people with past infection or a complete vaccination course: a global case series 40
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex 40
Immune recovery and T cell subset analysis during effective treatment with maraviroc 40
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 40
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 40
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 40
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 39
Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT) 39
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 39
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 39
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 38
Pustulosis acuta generalisata following chemotherapy in an HIV-positive patient 38
Vaccines against Emerging Sexually Transmitted Infections: Current Preventive Tools and Future Perspectives 37
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus 37
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 37
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 37
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 36
Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply 36
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 35
Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients 35
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection 35
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 35
Totale 5.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.112
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.112
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 7 2 11 1 0 1 0
2021/202273 0 0 0 20 7 9 3 6 4 11 3 10
2022/2023469 178 99 20 2 1 42 48 56 9 5 4 5
2023/2024559 9 19 99 48 64 125 21 58 1 15 30 70
2024/20252.693 196 35 75 78 123 224 712 316 267 201 166 300
2025/20263.351 606 530 474 1.060 649 32 0 0 0 0 0 0
Totale 7.219